Leerink Partnrs Brokers Lift Earnings Estimates for enGene

enGene Holdings Inc. (NASDAQ:ENGN - Free Report) - Research analysts at Leerink Partnrs raised their FY2026 EPS estimates for enGene in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($1.85) per share for the year, up from their prior forecast of ($1.89). The consensus estimate for enGene's current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for enGene's FY2027 earnings at ($1.74) EPS and FY2028 earnings at ($0.45) EPS.

Several other equities analysts have also recently weighed in on the company. Raymond James assumed coverage on shares of enGene in a research note on Wednesday, November 27th. They issued an "outperform" rating and a $23.00 price target on the stock. JMP Securities restated a "market outperform" rating and issued a $18.00 price target on shares of enGene in a research report on Monday, December 23rd. Citizens Jmp raised shares of enGene to a "strong-buy" rating in a research note on Monday, November 18th. Finally, HC Wainwright assumed coverage on shares of enGene in a report on Monday, December 23rd. They issued a "buy" rating and a $25.00 target price on the stock. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $29.78.

enGene Stock Performance

NASDAQ ENGN traded down $0.13 on Friday, hitting $7.16. The stock had a trading volume of 31,156 shares, compared to its average volume of 89,027. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08. enGene has a one year low of $4.42 and a one year high of $18.40. The company's 50-day moving average is $7.37 and its two-hundred day moving average is $7.54. The stock has a market cap of $316.62 million, a price-to-earnings ratio of -12.25 and a beta of -0.65.

enGene (NASDAQ:ENGN - Get Free Report) last announced its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.06.

Institutional Investors Weigh In On enGene

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. grew its stake in shares of enGene by 1,410.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company's stock valued at $4,376,000 after purchasing an additional 619,100 shares during the period. Franklin Resources Inc. grew its position in shares of enGene by 48.7% during the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company's stock worth $7,854,000 after purchasing an additional 389,918 shares in the last quarter. Finally, Wolverine Asset Management LLC bought a new position in shares of enGene during the third quarter worth $37,000. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.